Promising PTFE-coating technology of Optimus-CVS™ stents: The new player for congenital heart disease interventions
2022

New Stent Technology for Heart Disease

Sample size: 3 publication Evidence: moderate

Author Information

Author(s): Haddad Raymond N., Bonnet Damien, Alsac Jean-Marc, Malekzadeh-Milani Sophie

Primary Institution: M3C-Necker, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Paris, France

Hypothesis

Can the Optimus-CVS stent improve outcomes in congenital heart disease interventions?

Conclusion

Optimus-CVS appears to be a reliable high-performing alternative for treating congenital heart disease.

Supporting Evidence

  • The Optimus-CVS stent was successfully implanted in three patients.
  • Procedures were straightforward with minimal stent shortening.
  • No stent failures were recorded during short-term follow-up.

Takeaway

A new type of stent called Optimus-CVS is being tested to help kids with heart problems, and it seems to work really well.

Methodology

Three patients with congenital heart disease received the Optimus-CVS stent during December 2020, and their outcomes were assessed.

Limitations

The maximum available length of the stent may be short for some procedures, and there are concerns about aneurysms at the stent extremities.

Participant Demographics

Three patients with congenital heart disease, including a 20-year-old female, a 31-year-old male, and a 33-year-old female.

Digital Object Identifier (DOI)

10.1016/j.ijcchd.2022.100323

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication